Alkem Laboratories Limited Overview
Alkem Laboratories is India's sixth-largest pharmaceutical company by value in the Indian Pharmaceutical Market (IQVIA SSA MAT March 2026) and third-largest by prescriptions (SMSRC MAT February 2026), with a five-decade franchise built on acute-care mega-brands — most notably Clavam (amoxicillin-clavulanate), the PAN pantoprazole family (the second-largest brand family in the IPM), Taxim and A to Z. It has led the anti-infectives therapy area in India for more than 15 years. Roughly two-thirds of FY26 revenue of INR 147.1 bn came from India, with the balance from a US generics business (Ascend Laboratories, ~20% of sales) and a fast-growing non-US international portfolio (~12%). Under a promoter-family governance model, Alkem is repositioning toward chronic therapies (anti-diabetics including semaglutide, neuro, derma, cardiac), biosimilars and CDMO via Enzene Biosciences, and medical devices via Alkem MedTech — the last now anchored by the July 2026 acquisition of a controlling stake in Swiss structural-heart device maker Occlutech. It carries a net-cash balance sheet (INR 57.6 bn at 30 June 2026).
Company's own description
In its Q1 FY27 press release (14 August 2026), Alkem describes itself as the sixth-largest pharmaceutical company in the Indian market with more than 50 years of heritage, a dominant position in anti-infectives, gastrointestinal, pain management and supplements, and a growing chronic portfolio spanning diabetes, neurology, dermatology and urology. It states that it operates 20 manufacturing facilities and R&D centres producing generic formulations, active pharmaceutical ingredients (APIs) and biosimilars, and that outside India it has a meaningful presence in the US, Latin America, Australia, Europe and several Asian markets. Its corporate purpose line is "Inspiring Healthier Lives". For statutory segment reporting the company reports a single business segment — pharmaceuticals — with geographic disclosure of India and international (Morningstar profile; company filings).
Independent characterization
Alkem is best characterized as a domestic branded-generics franchise with three option-value adjacencies bolted onto a cash-generative core:
-
India branded generics (≈62–63% of sales after trade generics carve-out). Prescription-driven, field-force-led promotion of branded generics through ~14,000 medical representatives to general practitioners, consulting physicians and specialists. Pricing is partially regulated: BOB Capital Markets estimated that roughly 30% of sales fall under India's National List of Essential Medicines (NLEM) price controls (Q3 FY25 Result Review, 8 February 2025).
-
India trade generics (historically ~20% of domestic sales). Unbranded or lightly branded generics sold through distributors/retailers rather than promoted to doctors; carved out into wholly owned subsidiary Alkem Wellness Limited effective 1 October 2025. Alkem describes itself as a "leading player in the trade generics segment" (Q4 FY26 presentation).
-
US generics (≈20% of sales). Oral solids and other generic formulations sold under the Ascend Laboratories front end, supplied from Indian plants (Daman, Baddi) and US API capacity (California). Includes Enzene's US CDMO revenue in reported US figures (Q4 FY26 presentation footnote).
-
Non-US international (≈12% of sales; fastest-growing). Branded and generic sales in Australia (Pharmacor), Chile/Latin America, Philippines, Kazakhstan, Europe and the Middle East (new Saudi JV and Dubai subsidiaries).
-
Biosimilars and CDMO (Enzene Biosciences). Biosimilar development and manufacturing in Pune, India and a US CDMO facility; 6–7 biosimilars in the Indian portfolio per BOB Capital Markets (Q1 FY27 Result Review, 14 August 2026).
-
Medical devices (Alkem MedTech). Orthopaedic implants (Bombay Ortho, renamed Alkem MedTech Ortho; Advita Ortho/Exactech licensing in India) and, since July 2026, structural-heart occluders via Occlutech. Management stated MedTech contributed less than 1% of revenue before Occlutech (Q4 FY26 earnings call, 28 May 2026).
Revenue model and value-chain position
| Dimension | Characterization |
|---|---|
| Product vs. service mix | Overwhelmingly product revenue (finished dosage formulations, APIs, nutraceuticals, biosimilars, implants). Service revenue limited to Enzene CDMO (contract development/manufacturing) — not separately disclosed |
| Subscription / licensing | No subscription revenue; in-licensing and out-licensing deals exist but licensing income not separately disclosed |
| Value chain position | Vertically integrated: API manufacture (Ankleshwar, Mandva, California) → formulation (Baddi, Daman, Sikkim and others) → own distribution and field-force marketing in India; US front end via Ascend |
| Customer types | Indian physicians (prescribers), chemists/distributors/stockists, hospitals; US wholesalers, retail pharmacy chains, group purchasing organisations; international distributors and tender buyers; CDMO clients (biopharma companies) |
| End markets | Human pharmaceuticals (acute and chronic), nutraceuticals/consumer wellness, biologics, orthopaedic and cardiovascular devices |
| Other operating income | FY26 "revenue as reported" including other income was INR 152,956 M vs. revenue from operations of INR 147,123 M (StockAnalysis standardized) |
Strategy
Stated strategic themes
Synthesizing the FY26 results communication and Q1 FY27 MD commentary, Alkem's stated themes are:
-
Outperform the Indian market — sustain IPM outperformance through mega-brand building in acute therapies while scaling chronic (FY27 guidance: 100–150 bps outperformance).
-
Chronic transition — increase chronic contribution, led by anti-diabetics/obesity (semaglutide), derma (Adroit), respiratory and cardiac.
-
Differentiated international growth — a "differentiated launch pipeline for international markets" (Dr. Vikas Gupta, Q4 FY26 release), with US limited-competition launches (tolvaptan) and accelerated non-US expansion.
-
Margin discipline — business mix improvement, operating leverage and cost discipline (FY27 EBITDA margin guidance 20–21%).
-
Build next-phase growth engines — R&D, MedTech and Biotech, "in a disciplined manner" (Sandeep Singh, Q1 FY27 release).
-
Fix the core — strengthen execution, address operational and regulatory priorities, improve consistency (Q1 FY27 release).
Strategic initiatives (last 24 months)
| Initiative | Date | Description | Status |
|---|---|---|---|
| Trade generics carve-out | Dec 2024 → 1 Oct 2025 | Slump-sale transfer to Alkem Wellness for agility and focus on under-served markets | Completed |
| Network rationalization | Jan 2025 | Sale of Indore plant to Rubicon Research | Completed; gain INR 142.9 M in FY26 |
| Dermatology expansion | Feb–Apr 2025 | Adroit Biomed acquisition (INR 140 cr) | Integrated |
| MedTech platform — orthopaedics | Feb–Apr 2025 | Bombay Ortho (INR 147 cr); Advita Ortho licensing | Integrated |
| Saudi Arabia JV | Aug 2025 | 51:49 subsidiary with local partner | Formation stage |
| Biosimilar oncology launch | 2,025 | Pertuza (pertuzumab) in India | Launched |
| MedTech platform — cardiovascular | Feb–Jul 2026 | Occlutech 51–55% for EUR 99.4 M | Completed; integration under way |
| Gulf presence | Feb–Mar 2026 | Two Dubai subsidiaries | Incorporated |
| GLP-1 entry | Mar 2026 | Day-one semaglutide launch; pre-filled syringe at INR 350 | ~11% unit share early |
| Consumer wellness | Apr 2026 | A to Z Daily launch | Launched |
| Capacity — Ujjain greenfield | Mar 2026 | Up to INR 533 cr, ~30 acres | Under development |
| Capacity — Baddi block | Aug 2026 | Up to INR 75 cr | Approved |
| US limited-competition launch | Sep–Oct 2026 (guided) | Generic tolvaptan (Jynarque) | Launch confirmation pending |
Management guidance (FY27)
| Parameter | Guidance | Source |
|---|---|---|
| India growth | Outperform IPM by 100–150 bps; double-digit domestic growth targeted | Q4 FY26 call |
| EBITDA margin | 20–21% (broadly in line with FY26) | Q4 FY26 call |
| Tax | Shift to new regime, 25% base rate, from April 2026 | Q4 FY26 call (Sahi) |
| US | Tolvaptan launch Sept–Oct 2026, contribution in H2 | Q4 FY26 call |
| R&D | Not quantified; rising (Q1 FY27 at 4.0% vs 3.5%) | Q1 FY27 release |
ESG commitments: specific quantified emissions or sustainability targets were not identified in reviewed sources. Cost programmes: no named programme with quantified targets disclosed; cost discipline is cited qualitatively.
Products & Services
Alkem markets 800+ brands in India (Q3 FY23 Press Release). Product-level revenue is not disclosed except for brand-family thresholds. The following catalog is organized by business line and therapy; where a specific attribute is not disclosed, it is marked accordingly.
India — brand-family scale (IQVIA SSA MAT March 2026)
| Brand-family size band | Count MAT Mar'21 | Count MAT Mar'26 | 5-year CAGR (%) |
|---|---|---|---|
| Above INR 10 bn | 0 | 1 | 15.2 |
| Above INR 5 bn | 1 | 1 | 12.4 |
| Above INR 1.5 bn | 5 | 12 | 12.4 |
| Above INR 500 M (Q1 FY27 deck shows 17) | 15 | 16 | 11.2 |
Source: Q4 FY26 and Q1 FY27 Results Presentations. Additional disclosures: 15 brands rank in the IPM Top 300; 36–37 brands (>INR 250 M) rank top-3 in their covered market; 17–20 brand families exceed INR 1 bn (figures differ between the two decks — flagged).
India — flagship brands by therapy
| Therapy | Flagship brand(s) | Molecule / description | Target prescriber | Status / data point |
|---|---|---|---|---|
| Gastrointestinal | PAN, PAN-D (PAN family) | Pantoprazole; pantoprazole + domperidone | GPs, gastroenterologists, physicians | PAN family crossed INR 10 bn in 2022; second-largest brand family in IPM (Q4 FY26 deck) |
| Anti-infectives | Clavam | Amoxicillin + clavulanic acid | GPs, paediatricians, ENT, physicians | Crossed INR 6 bn in 2022 |
| Anti-infectives | Taxim, Taxim-O | Cefotaxime (injectable); cefixime (oral) | GPs, physicians, hospitals | First anti-infective in India to cross INR 1 bn (2006) |
| VMN / supplements | A to Z; A to Z Daily | Multivitamin-multimineral; everyday wellness variant launched 7 April 2026 | GPs, consumers | A to Z Daily launch per exchange press release (Sharekhan news log) |
| VMN | Gemcal, Uprise-D3 | Calcium/vitamin D3 combinations; vitamin D3 | Orthopaedics, gynaecologists | Brand names per company historical portfolio; individual sales not disclosed |
| Pain / analgesics | Not individually disclosed | NSAIDs, combinations | Orthopaedics, GPs | Alkem pain portfolio grew 1.8x IPM in Q1 FY27 |
| Anti-diabetic / obesity | Semaglutide injectable; single-shot pre-filled syringe format from INR 350 | GLP-1 receptor agonist | Diabetologists, endocrinologists | Day-one launch March 2026; ~11% unit share in early IQVIA reports (Q4 FY26 call) |
| Dermatology | Glutone, SkinFay, Racine, FortiSil (Adroit) | Skin-lightening/antioxidant, skincare, hair and nail supplements | Dermatologists, cosmetologists | Adroit FY24 revenue INR 53.55 cr (BioSpectrum) |
| Respiratory | Pulmocare division portfolio | Inhalers and respiratory formulations | Pulmonologists, chest physicians | Division launched 2021 |
| Neuro / CNS | Portfolio not individually disclosed | Antiepileptics, antidepressants etc. | Neurologists, psychiatrists | Only key therapy where Alkem under-indexed IPM growth in Q1 FY27 (8.7% vs 12.0%) |
| Oncology (biosimilar) | Pertuza | Pertuzumab biosimilar (Enzene) | Oncologists | Launched 2025 (scanx news log) |
| Bone health (biosimilar) | Teriparatide (Enzene) | Recombinant PTH analogue | Endocrinologists, orthopaedics | Enzene India portfolio of 6–7 biosimilars (BOB Capital Markets) |
India — therapy-wise market position (IQVIA SSA)
| Therapy | FY26 IPM growth (%) | FY26 Alkem growth (%) | FY26 market share (%) | FY26 IPM rank | Q1FY27 Alkem growth (%) | Q1FY27 IPM growth (%) | Q1FY27 market share (%) | Q1FY27 rank |
|---|---|---|---|---|---|---|---|---|
| Anti-infectives | 4.0 | 4.4 | 13.2 | 1 | 7.9 | 6.9 | 13.3 | 1 |
| Gastrointestinal | 5.7 | 8.3 | 7.9 | 4 | 12.2 | 10.2 | 7.9 | 4 |
| VMN | 9.2 | 18.4 | 6.7 | 2 | 21.4 | 15.1 | 6.8 | 2 |
| Pain / analgesics | 7.2 | 11.6 | 5.4 | 3 | 20.2 | 11.5 | 5.6 | 3 |
| Anti-diabetic | 11.5 | 14.2 | 2.2 | 15 | 21.1 | 15.5 | 2.3 | 13 |
| Neuro / CNS | 9.8 | 8.6 | 1.6 | 15 | 8.7 | 12.0 | 1.5 | 14 |
| Respiratory | 11.3 | 16.2 | 2.4 | 8 | 16.8 | 10.5 | 2.4 | 8 |
| Dermatology | 6.1 | 11.2 | 1.5 | 18 | 16.5 | 10.3 | 1.6 | 19 |
Source: Q4 FY26 Results Presentation (IQVIA SSA MAT Mar'26); Q1 FY27 Results Presentation (IQVIA SSA Qtr Jun'26). Column assignments reconciled against the company's stated count of outperforming therapies.
Trade generics (Alkem Wellness)
Unbranded/low-promotion generic formulations sold to distributors and retail chemists, targeting affordability in under-served markets. Business delivered more than INR 10 bn topline in 2020 (company milestone). Management guided trade generics growth broadly in line with IPM (BOB Capital Markets, Q4 FY25 review); Q1 FY27 trade generics growth was "flattish" while branded generics grew ~12% (BOB Capital Markets, Q1 FY27 review). Pricing model: trade discounts to distributors; specifics not publicly disclosed.
US generics (Ascend Laboratories)
| Attribute | Detail |
|---|---|
| Portfolio scale | 192 ANDAs filed, 2 NDAs, 1 BLA; 170 ANDA approvals (incl. 18 tentative) and 2 NDA approvals as of 30 June 2026 (Q1 FY27 presentation) |
| FY26 activity | 8 ANDAs and 1 BLA filed; 17 ANDA approvals; 11 product launches (Motilal Oswal, 28 May 2026) |
| Q1 FY27 activity | 5 ANDA approvals (1 tentative) |
| Near-term flagship | Generic tolvaptan (reference: Jynarque, ADPKD) — USFDA approval received October 2023; management guided launch September–October 2026 as a limited-competition product (Q4 FY26 call). Launch confirmation not found as of 19 October 2026. Context: Lupin launched with 180-day exclusivity in May 2025; Jynarque US sales were ~USD 1.47 bn in CY2024 (Lupin press release) |
| Historical flagship | Generic tolvaptan 30 mg (reference: Samsca), launched May 2020 alongside Apotex (OptumRx) |
| Pricing model | Wholesale/GPO contract pricing; not disclosed |
Non-US international
Branded and branded-generic formulations in Australia (Pharmacor), Chile and broader Latin America, Philippines, Kazakhstan/CIS, Europe and the Middle East; Q1 FY27 non-US growth of 34.5% was driven by "double-digit growth across key markets" (Q1 FY27 presentation). Product-level detail not publicly disclosed.
Biosimilars and CDMO (Enzene Biosciences)
| Offering | Description | Status |
|---|---|---|
| India biosimilars | 6–7 biosimilars including teriparatide and pertuzumab (Pertuza) | Marketed in India; portfolio size per BOB Capital Markets (Aug 2026) |
| US BLA | 1 BLA filed with USFDA (FY26) | Under review (molecule not disclosed in reviewed sources) |
| CDMO — India | Biologics development and manufacturing for third parties at Pune | Operational |
| CDMO — US | US biologics CDMO facility; adds ~INR 600 M of operating expenses (BOB Capital Markets, Q1 FY27 review) | Ramp-up; operating deleverage noted by analysts |
Medical devices (Alkem MedTech)
| Offering | Description | Origin |
|---|---|---|
| Hip and knee implants | Orthopaedic joint replacement implants manufactured in India | Bombay Ortho (acquired April 2025 for INR 147 cr) |
| Advita Ortho (Exactech) portfolio | Licensed orthopaedic implant portfolio for India | Licensing agreement 2024–25 |
| Structural-heart occluders | Devices for congenital heart disease (septal defect occluders), stroke prevention (left atrial appendage/PFO closure) and heart failure (atrial flow regulation) | Occlutech (51–55% from July 2026); CY2025 revenue EUR 49.4 M (unaudited), 15.7% 3-year CAGR; ~85% of revenue from Europe and US |
Financial Narrative
Income statement (consolidated)
Source: StockAnalysis.com standardized consolidated income statement (FY22–FY26); FY25–FY26 EPS from Q4 FY26 Results Presentation; FY22–FY24 EPS derived as net income / 119.57 M shares (no change in share count since IPO).
Company-reported (non-standardized) reconciliation items:
Source: Q4 FY26 Results Presentation. FY26 exceptional items: INR 1,130.6 M labour-code gratuity/leave encashment past-service cost, INR 747 M impairment of real-estate investments, partly offset by INR 142.9 M gain on sale of the Indore facility. Discrepancy: company FY25 gross profit (82,003) and EBITDA (25,122) differ from standardized figures (80,391 and 24,619) due to classification; company figures are preferred for analysis. Company-reported FY24 EBITDA margin was 17.7% (Q4 FY25 Press Release).
Margin profile
Revenue CAGR FY22–FY26: 8.4% (derived: (147,123/106,342)^(1/4) − 1). FY23–FY26 CAGR: 8.3%.
Commentary. The five-year record shows two distinct regimes. FY22–FY23 was a period of margin compression: FY23 EBITDA margin collapsed to 13.7% (standardized) as US price erosion, elevated API/freight costs and a one-off tax-related item depressed earnings — net income fell 40%. FY24–FY26 has been a margin-rebuild phase under the cost-control programme associated with the September 2023 CEO appointment: company-reported EBITDA margin expanded from 17.7% (FY24) to 19.4% (FY25) to 20.4% (FY26), while gross margin widened from ~60% to 65.4%. Drivers cited by management include favourable API prices, cost-control initiatives, an improving business mix (higher chronic share, lower trade generics weight, non-US growth) and operating leverage (Q4 FY25 and Q4 FY26 press releases). The FY26 inflection in revenue growth (13.5% vs 2.3% in FY25) came from a US recovery (+20.3%) and non-US acceleration (+26.7%), with India also accelerating to 9.7%. Below EBITDA, FY26 net income growth (6.3%) lagged EBITDA growth (19.6%) due to INR 1.75 bn of exceptional charges, higher depreciation (new capacity, acquisitions) and a higher tax charge as SEZ benefits roll off.
Q1 FY27 inflection. Q1 FY27 revenue grew 10.9% to INR 37,402 M and gross margin reached a record 67.9%, but EBITDA margin fell to 20.5% from 21.9% because of higher R&D (INR 1,502 M, 4.0% of revenue), Enzene US CDMO operating costs and employee costs (INR 808.9 cr employee benefits expense). PAT fell 21.7% to INR 5,200 M primarily on higher taxation as the company migrated to India's new corporate tax regime (25% base rate) from April 2026 and Sikkim SEZ benefits expire (Quartr earnings summary; Sahi; BOB Capital Markets). Note: some secondary sources misreported Q1 FY27 PBT (INR 422.85 cr) and EPS (INR 19.77) — these appear to be Q4 FY26 figures; the company presentation shows PBT INR 7,720 M and EPS INR 43.5.
Balance sheet
Sources: FinancialFilings.com (FY26 total assets, equity, CFO, per earnings release of 28 May 2026); FY26 Directors' Report (other equity: consolidated INR 137,961.9 M FY26, INR 119,609.6 M FY25 — column assignment inferred); Q4 FY25 Press Release ("cash and balance" INR 46.2 bn, which may be gross rather than net); Q4 FY26 and Q1 FY27 presentations (net cash). FY22–FY24 balance-sheet line items, gross debt split (short/long term), goodwill and intangibles, and working capital were not publicly disclosed in reviewed sources and are not estimated here.
Commentary. Alkem is structurally net-cash. Net cash rose from INR 54.7 bn (March 2026) to INR 57.6 bn (June 2026) despite the final dividend record date falling in August; the July 2026 Occlutech payment (EUR 99.4 M ≈ INR 1,074 cr) will reduce Q2 FY27 net cash by roughly INR 10.7 bn and add goodwill/intangibles and Occlutech's balance sheet on consolidation. Book value per share is approximately INR 1,156 at FY26 (derived: 138,201/119.57); a Business Standard reference of INR 1,116 likely reflects an earlier reporting date.
Cash flow
Sources: FinancialFilings.com (CFO); BOB Capital Markets Q4 FY25 review (FY26 capex guidance); dividend declarations (interim INR 43 per share, February 2026; final INR 10 per share, record date 7 August 2026, paid from 1 September 2026). Historical OCF, capex and FCF for FY22–FY25 were not publicly disclosed in reviewed sources. FY26 OCF/net income conversion of ~85% (19,630/23,018) suggests working-capital absorption during a year of 13.5% growth. Indicative FY26 FCF, if capex was near guidance, would be ~INR 12–12.6 bn — this is an estimate from guidance, not a disclosed figure.
Commentary. H1 FY25 cash generation of ~INR 12.0 bn (BOB Capital Markets, Q2 FY25 review) and the progression of cash balances from INR 46.2 bn to INR 57.6 bn over five quarters — while paying ~INR 6 bn of annual dividends and funding Adroit and Bombay Ortho (~INR 2.9 bn combined) — demonstrate strong underlying FCF. Capital intensity is rising: Ujjain greenfield (up to INR 533 cr), Baddi block (up to INR 75 cr, August 2026), Enzene US CDMO, and Occlutech.
Ratios
Sources: derived from figures above; ROCE from Q4 FY26 Results Presentation. Current ratio, debt/equity and cash conversion cycle are not publicly disclosed in reviewed sources. ROIC is not disclosed; ROCE is the closest company metric. Screener.in shows ROE 19.6% and ROCE 19.7% on its own (post-tax, different denominator) methodology — not directly comparable.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Segment Revenue
| Segment | Contents | FY2024 revenue (INR Mn) | FY2025 revenue (INR Mn) | FY2026 revenue (INR Mn) | YoY FY26 (%) | % of total FY26 |
|---|---|---|---|---|---|---|
Pharmaceuticals (sole reportable segment) | Branded generics, trade generics, US generics, international formulations, APIs, biosimilars, CDMO, nutraceuticals, medical devices | 126,676 | 129,645 | 147,123 | 13.5 | 100.0 |
Business Lines
| Business line (sales, INR Mn) | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
India business (incl. Adroit and Alkem MedTech from FY26) | 84,337 | 89,837 | 98,514 |
US business (incl. Enzene US CDMO; FY24 derived from 22.3% share) | 27,739 | 24,818 | 29,845 |
Non-US international (FY24 derived from 9.9% share) | 12,315 | 13,392 | 16,964 |
Business line YoY growth (%)
| Business line YoY growth (%) | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
India business | 5.4 | 6.5 | 9.7 |
US business (FY25 derived) | — | -10.5 | 20.3 |
Non-US international | — | 8.7 | 26.7 |
Business line % of total sales (%)
| Business line % of total sales (%) | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
India business | 67.8 | 70.2 | 67.8 |
US business | 22.3 | 19.4 | 20.5 |
Non-US international | 9.9 | 10.5 | 11.7 |
Revenue by Segment and Segment Margins & Growth (%)
| Metric (INR Mn) | Q1FY26 | Q2FY26 | Q3FY26 | Q4FY26 | Q1FY27 |
|---|---|---|---|---|---|
Revenue from operations (Q2 derived) | 33,711 | 40,011 | 37,368 | 36,033 | 37,402 |
India sales | 22,650 | — | — | 23,245 | 24,978 |
US sales | 6,982 | — | — | 7,681 | 7,439 |
Non-US sales | 3,556 | — | — | 4,543 | 4,785 |
EBITDA (Q2 derived) | 7,391 | 9,207 | 8,280 | 5,174 | 7,661 |
EBITDA margin (%) | 21.9 | 23.0 | 22.2 | 14.4 | 20.5 |
PAT after NCI (Q2 derived) | 6,643 | 7,650 | 6,360 | 2,365 | 5,200 |
Group Entities
| Entity | Role | Ownership |
|---|---|---|
Alkem Laboratories Ltd | Parent; India branded generics, manufacturing, R&D | Listed |
Alkem Wellness Ltd | Trade generics business (from 1 Oct 2025) | Wholly owned |
Adroit Biomed Ltd | Dermatology/cosmetology brands | Wholly owned (from 23 Apr 2025) |
Alkem MedTech Pvt Ltd | Medical devices holding/operating company | Wholly owned |
Alkem MedTech Ortho Pvt Ltd (formerly Bombay Ortho Industries) | Hip and knee implants manufacturing | Wholly owned step-down |
Occlutech Holding AG (Switzerland) | Structural-heart occluder devices | 51–55% via Alkem MedTech (from July 2026) |
Enzene Biosciences Ltd (and US CDMO entity) | Biosimilars, biologics CDMO | — |
Ascend Laboratories LLC / ThePharmaNetwork LLC (US) | US generics marketing | Wholly owned |
S&B Pharma (US) | API manufacturing, California | — |
Pharmacor Pty Ltd (Australia) | Australian generics | Wholly owned |
| — | Manufacture, import, marketing and distribution in KSA | 51% (Abdulaziz Alsheikh 49%) |
Alkem Pharmaceuticals Scientific Office FZ-LLC (Dubai) | Scientific office | Wholly owned (incorporated 4 Feb 2026) |
Alkem Pharma Trading FZCO (Dubai) | Trading | Wholly owned (incorporated 27 Mar 2026) |
Income Statement and Margin Analysis (%)
| Metric (INR Mn unless stated) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Revenue from operations | 106,342 | 115,993 | 126,676 | 129,645 | 147,123 |
Revenue growth (%) | 19.96 | 9.07 | 9.21 | 2.34 | 13.48 |
Gross profit (standardized) | 63,536 | 65,785 | 76,034 | 80,391 | 96,195 |
Operating income EBIT (standardized) | 17,432 | 13,196 | 19,676 | 21,518 | 26,232 |
EBITDA (standardized) | 20,122 | 15,893 | 22,268 | 24,619 | 30,052 |
Depreciation and amortization | 2,690 | 2,697 | 2,592 | 3,101 | 3,821 |
Interest expense | 309 | 809 | 971 | 1,048 | 1,608 |
Net income attributable to owners | 16,456 | 9,842 | 17,958 | 21,655 | 23,018 |
Net income growth (%) | 3.82 | -40.20 | 82.47 | 20.59 | 6.30 |
EPS basic and diluted (INR; FY22–FY24 derived) | 137.6 | 82.3 | 150.2 | 181.1 | 192.5 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansIncome Statement
| Metric (INR Mn) | FY2025 | FY2026 |
|---|---|---|
Gross profit (company) | 82,003 | 96,195 |
EBITDA (company) | 25,122 | 30,052 |
PBT before exceptional items | 25,270 | 30,457 |
Exceptional items | 0 | -1,748 |
PBT after exceptional items | 25,270 | 28,709 |
PAT after non-controlling interest | 21,655 | 23,018 |
Margin (%)
| Margin (%) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Gross margin (standardized) | 59.7 | 56.7 | 60.0 | 62.0 | 65.4 |
Gross margin (company-reported) | — | — | — | 63.3 | 65.4 |
Operating (EBIT) margin | 16.4 | 11.4 | 15.5 | 16.6 | 17.8 |
EBITDA margin (standardized) | 18.9 | 13.7 | 17.6 | 19.0 | 20.4 |
EBITDA margin (company-reported) | — | — | 17.7 | 19.4 | 20.4 |
Net margin | 15.5 | 8.5 | 14.2 | 16.7 | 15.6 |
Balance Sheet
| Metric (INR Mn) | FY2025 | FY2026 | Q1FY27 |
|---|---|---|---|
Total assets | — | 208,730 | — |
Total equity incl. NCI | — | 143,490 | — |
Equity attributable to owners (derived: share capital + consolidated other equity) | 119,849 | 138,201 | — |
Cash and bank balances / net cash | 46,200 | 54,740 | 57,640 |
Share capital | 239.1 | 239.1 | 239.1 |
Cash Flow and Dividends & Capital Returns (INR)
| Metric (INR Mn) | FY2026 |
|---|---|
Operating cash flow | 19,630 |
Dividends declared for FY26 (INR 53/share; derived) | 6,337 |
Share buybacks | 0 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2025 | FY2026 |
|---|---|---|
ROE (%, derived on average attributable equity) | — | 17.8 |
ROA (%, derived on period-end total assets) | — | 11.0 |
ROCE pre-tax (%, company; Q1 FY27 deck shows 29.6) | — | 29.4 |
Interest coverage (EBIT / interest, x) | 20.5 | 16.3 |
Net debt / EBITDA (x; negative = net cash) | — | -1.8 |
Asset turnover (x, derived) | — | 0.70 |
Revenue by Region
| Region (sales, INR Mn) | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
India | 84,337 | 89,837 | 98,514 |
United States (FY24 derived) | 27,739 | 24,818 | 29,845 |
Rest of world / non-US international (FY24 derived) | 12,315 | 13,392 | 16,964 |
Total sales (sum) | 124,391 | 128,047 | 145,323 |
Region growth (%)
| Region growth (%) | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
India | 5.4 | 6.5 | 9.7 |
United States (FY25 derived) | — | -10.5 | 20.3 |
Rest of world | — | 8.7 | 26.7 |
Share Price History
| Date | NSE price (INR) | Source |
|---|---|---|
7 Jan 2026 | 5,785.60 | Business Standard |
27 Feb 2026 | 5,658.75 | Business Standard |
31 Mar 2026 | 5,299 | Q4 FY26 presentation |
24 Apr 2026 | 5,366 | BusinessLine (CEO exit day) |
27 May 2026 | 5,452 | BOB Capital Markets |
30 Jun 2026 | 5,570 | Q1 FY27 presentation |
31 Jul 2026 | 5,751.50 | Value Research |
14 Aug 2026 | ~5300 | Multibagg (post-results) |
17 Sep 2026 | 5,193 | Anand Rathi |
24 Sep 2026 | 5,337 | Angel One |
Performance | Value | Source / date |
1-year return (%) | -5.3 | Anand Rathi, 17 Sep 2026 |
3-year return (%) | 41.1 | Anand Rathi, 17 Sep 2026 (Value Research shows 12.9% as of 31 Jul 2026 — methodology/date discrepancy) |
52-week high / low (INR) | 5933.50 / ~4738.50 (Aug 2026); 5933 / 5052.05 (Sep 2026, per Anand Rathi) | Value Research; Anand Rathi |
All-time high (INR) | 6,439.90 | Anand Rathi |
IPO (Dec 2015) | Offer for sale, no fresh issue | Pharma Focus Asia |
Valuation Multiples
| Multiple | Alkem | Basis |
|---|---|---|
P/E (TTM) | ~27x | Anand Rathi, 17 Sep 2026 (26.96x) |
P/B | ~4.9x | Anand Rathi |
EV/EBITDA (TTM, derived) | ~18.6x | Mcap ~INR 62,000 cr less net cash ~INR 5,764 cr; TTM EBITDA ~INR 3,032 cr |
EV/Sales (TTM, derived) | ~3.7x | TTM revenue ~INR 15,081 cr |
Forward P/E | ~29x FY27E, ~26x FY28E | MOFSL, 28 May 2026 (at INR 5,452) |
Peer median P/E | ~38x (Value Research, 31 Jul 2026; Alkem at 21% discount) | Value Research |
Analyst Ratings & Targets
| Broker | Date | Rating | Target (INR) | Key view |
|---|---|---|---|---|
Motilal Oswal | 28 May 2026 | Neutral | 5,840 | 28x 12-month forward EPS; export momentum and domestic revival offset by biosimilar costs |
BOB Capital Markets | 29 May 2026 | Sell | 4,638 | Margins flat in FY27; valuation expensive; FY27E revenue INR 163,093 M, EBITDA INR 32,619 M, adj. PAT INR 22,668 M |
BOB Capital Markets | 14 Aug 2026 | Sell | 4,590 | Enzene CDMO deleverage; EBITDA margin 19.7% FY27E, 20.8% FY28E |
Nomura | May 2026 | Not stated | Not stated | FY27 guidance in line to ahead |
S&P Global consensus (via INDmoney) | 2026 | — | 5557 (average) | Slight upside at the time |
Per-Share Data and Returns & Leverage Ratios (%)
| Item | FY2026 |
|---|---|
Interim dividend per share (INR) | 43 |
Final dividend per share (INR) | 10 |
Total dividend per share (INR) | 53 |
Payout ratio (derived, % of PAT) | 27.5 |
Analyst Conclusions
Guidance and consensus
Management guides FY27 India growth 100–150 bps ahead of IPM, EBITDA margin of 20–21%, and an H2 contribution from US tolvaptan. Q1 FY27 delivered 20.5% EBITDA margin and 100 bps IPM outperformance — at the low end on both.
Bull case
-
Chronic re-rating catalyst: semaglutide's ~11% early unit share, plus anti-diabetic growth of 21.1% in Q1 FY27 (1.4x IPM), can lift chronic mix and margins.
-
US earnings step-up: a limited-competition tolvaptan launch against a ~USD 1.47 bn reference market could add meaningfully to H2 FY27 US sales, offsetting price erosion.
-
Optionality funded by net cash: INR 57.6 bn net cash plus a 65–68% gross margin supports MedTech (Occlutech) and biosimilars without equity dilution, at ~27x trailing P/E — a discount to the ~38x peer median.
Bear case
-
Regulatory escalation: the Daman OAI could become a warning letter or import alert, freezing approvals and impairing US growth (US sales grew only 6.5% in Q1 FY27).
-
Leadership vacuum: CEO and CFO exits during the largest acquisition integration in company history raise execution risk; the MD has acknowledged execution gaps.
-
Earnings drag from tax and investment: the 25% tax regime, SEZ expiry, Enzene US CDMO opex and Occlutech amortization could keep EPS flat-to-down in FY27 (Q1 FY27 EPS −21.7%), undermining the multiple.
Catalysts and monitorables (next 12 months)
| Catalyst / monitorable | Expected timing |
|---|---|
| Q2 FY27 results (first quarter including Occlutech; tolvaptan launch confirmation) | By 14 November 2026 |
| CEO and CFO appointments | Pending |
| USFDA response to Daman remediation (warning letter vs. re-inspection) | FY27 |
| Semaglutide share trajectory and pricing | Monthly IQVIA |
| Occlutech integration and first consolidated MedTech disclosure | H2 FY27 |
| US BLA review outcome (Enzene) | — |
| Ujjain and Baddi capacity commissioning | FY27–FY28 |
| Further promoter stake sales | Ongoing risk |
| FY28 guidance | May 2027 |
Analyst verdict
Alkem enters the second half of FY27 as a fundamentally sound franchise wrapped in an unusually busy transition. The core is strong: leadership in anti-infectives, a mega-brand machine that has more than doubled its INR 1.5 bn-plus brand families in five years, record FY26 EBITDA of INR 30.1 bn at a 20.4% margin, a 65–68% gross margin and INR 57.6 bn of net cash. The FY24–FY26 margin rebuild was real and largely structural, rooted in mix improvement, procurement and cost discipline rather than one-offs.
Against that, 2026 has stacked three uncertainties on top of each other. First, governance continuity: the professional CEO left in June and the CFO in September, leaving the promoter-MD to steer the Occlutech integration, a CDMO ramp and a regulatory remediation simultaneously. Second, regulatory: the Daman OAI is the most material quality event for Alkem in several years and directly touches the US business, which had only just recovered. Third, earnings optics: tax normalization will likely flatten FY27 EPS despite double-digit revenue and stable EBITDA, which matters for a stock that trades on earnings multiples.
The investment debate therefore hinges less on Alkem's franchise quality — which is not in question — and more on execution over the next two to three quarters. Successful tolvaptan and semaglutide scaling, a credible CEO appointment and a contained Daman outcome would validate the strategy and justify a multiple closer to large-cap peers, given superior balance-sheet strength. Conversely, a warning letter combined with prolonged leadership vacancy would likely keep the stock range-bound near its 52-week band (~INR 4,700–5,900), as analyst targets spanning INR 4,590 (Sell) to INR 5,840 (Neutral) already suggest. On balance, the evidence supports a neutral stance with positive skew: the downside is cushioned by net cash and a ~27x trailing multiple below the peer median, while the upside requires visible evidence that the 2026 transition is being managed, not merely endured.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Tenure / key dates | Background | Age | FY26 compensation |
|---|---|---|---|---|---|
Basudeo Narain (B.N.) Singh | Executive Chairman | Co-founder (1973) | Founder-promoter; led Alkem since inception | Not disclosed in reviewed sources | Not publicly disclosed in reviewed sources (refer FY26 Annual Report remuneration disclosures) |
Sandeep Singh | Managing Director; de facto lead executive since CEO exit | Joint MD at IPO (2015); MD thereafter | Promoter family; leads Q1 FY27 investor communication | — | Not publicly disclosed in reviewed sources |
Madhurima Singh | Executive Director | Appointed November 2023; re-appointed for five years from 20 December 2026 (board approval 28 May 2026, subject to AGM) | Promoter family; stake rose to 6.18% in March 2025 via transmission from estate of late Dhananjay Kumar Singh | — | Not publicly disclosed in reviewed sources |
Rajeev Kher | Independent Director | Appointed October 2024 | — | — | Sitting fees/commission not disclosed in reviewed sources |
Kaustav Banerjee | CEO, Alkem MedTech | Senior management since December 2023 | Led Occlutech transaction | — | — |
Manish Narang | President – Legal, Company Secretary & Compliance Officer | Signatory on 2025–26 filings | Legal/secretarial | — | — |
Chanakya Misra | Senior Management Personnel | From 18 May 2026 | Role not specified in reviewed sources | — | — |
Dr. Shubhadeep Sinha | Senior Management Personnel | From 15 September 2026 | 25+ years in clinical development, medical affairs, pharmacovigilance, regulatory affairs | — | — |
Sunil Sawant | Senior Management Personnel | From 16 December 2025 | Role not specified in reviewed sources | — | — |
Purvi Shah | Head of Investor Relations | Current | IR | — | — |
Chief Executive Officer | Vacant | Dr. Vikas Gupta departed 30 June 2026; global search firms engaged (FilingReader, 1 June 2026) | — | — | — |
Chief Financial Officer | Vacant / successor not identified in reviewed sources | Nitin Agrawal resigned effective 30 September 2026 | Agrawal led MedTech vertical set-up and Adroit, Bombay Ortho, Alkem Wellness and Occlutech deals | — | — |
“—” = not publicly disclosed.
Board & Management Changes
| Date | Change | Context |
|---|---|---|
15 Sep 2023 | Dr. Vikas Gupta appointed CEO (effective 22 Sep 2023) | First professional CEO of the post-IPO era to drive margin turnaround |
Jan 2024 | CFO transition; Nitin Agrawal named successor to outgoing CFO | MarketScreener news log |
Jul 2024 | "Change in management" disclosed; Yogesh Kaushal retirement (SMP) | MarketScreener news log |
Feb 2025 | Sanjay Kumar Dipak appointed to senior management | MarketScreener |
30 Sep 2025 | Amit Ghare (SMP) steps down | Zonebourse/Medical Dialogues |
24 Apr 2026 | CEO Dr. Vikas Gupta resigns (effective 30 June 2026); stock fell 2.8% to INR 5,366 | BusinessLine via AskFuzz |
18 May 2026 | Chanakya Misra appointed SMP | MarketScreener |
15 Sep 2026 | Dr. Shubhadeep Sinha appointed SMP | Investywise (BSE) |
24 Sep 2026 | CFO Nitin Agrawal resignation disclosed (letter dated 30 July 2026; effective 30 Sep 2026) | Angel One; scanx |
Shareholding Trend
| Holder category (%) | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|
Promoter and promoter group | 51.2 | 49.7 |
Institutions (MF, AIF, FPI, FI/banks) | 31.5 | 33.1 |
Non-institutions | 17.3 | 17.3 |
Competitive Landscape
Competitors by Segment
| Business line | Competitors |
|---|---|
India acute (anti-infectives, GI, pain, VMN) | Abbott India, Mankind Pharma, Cipla, Sun Pharma, Intas (unlisted), Macleods (unlisted), Lupin, Alembic, Aristo (unlisted) |
India chronic (diabetes, cardiac, neuro, derma) | Sun Pharma, Torrent Pharma, Lupin, Mankind, Zydus Lifesciences, Glenmark, Intas, Dr. Reddy's |
Semaglutide / GLP-1 generics (India) | Multiple launches at patent expiry March 2026 (Sun, Dr. |
Trade generics | Mankind (via generics), Intas, regional generic houses |
US generics | Lupin, Zydus, Aurobindo, Dr. Reddy's, Sun, Cipla, Teva, Viatris, Apotex |
Biosimilars (India) | Biocon Biologics, Intas, Dr. Reddy's, Zydus, Reliance Life Sciences |
Structural heart devices | Abbott (Amplatzer), W. L. Gore, Boston Scientific (Watchman), Lifetech Scientific; Occlutech claims #2 in Europe, #3 globally in minimally invasive cardiac implants |
Orthopaedic implants (India) | Meril Life Sciences, Zimmer Biomet, Stryker, Smith & Nephew, DePuy Synthes |
Peer Comparison FY2025
| Company | Revenue FY25 (INR Cr, approx.) | Revenue growth FY25 (%, approx.) | EBITDA margin FY25 (%, approx.) | R&D % of sales FY25 (approx.) |
|---|---|---|---|---|
Alkem Laboratories (FY26 actual) | 14,712 | 13.5 | 20.4 | 4.2 |
Sun Pharmaceutical | ~52,000 | ~8 | ~28 | ~6 |
Cipla | ~27,500 | ~7 | ~26 | ~5 |
Mankind Pharma | ~12,200 | ~18 | ~25 | ~2 |
Torrent Pharmaceuticals | ~11,500 | ~6 | ~32 | ~4 |
Lupin | ~22,700 | ~13 | ~23 | ~8 |
Zydus Lifesciences | ~23,200 | ~19 | ~29 | ~7 |



